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Tamoxifen as an effective neuroprotectant
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involvement of inflammatory signaling
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Abstract
Background: Tamoxifen, a selective estrogen receptor modulator, has successfully been used to treat several animal
models of brain injury, but the underlying mechanisms remain unclear. This study was undertaken to evaluate the
effect of tamoxifen on the toll-like receptor 4 (TLR4)- and nuclear factor-κB (NF-κB)-related inflammatory signaling
pathway and secondary brain injury in rats after subarachnoid hemorrhage (SAH).
Methods: Adult male Sprague-Dawley rats were divided into four groups: (1) control group (n = 28); (2) SAH group
(n = 28); (3) SAH + vehicle group (n = 28); and (4) SAH + tamoxifen group (n = 28). All SAH animals were subjected to
injection of autologous blood into the prechiasmatic cistern once on day 0. In SAH + tamoxifen group, tamoxifen was
administered intraperitoneally at a dose of 5 mg/kg at 2 h, 12 h, and 36 h after SAH. In the first set of experiments, brain
samples were extracted and evaluated at 48 h after SAH. In the second set of experiments, the Morris water maze was
used to investigate cognitive and memory changes.
Results: We found that treatment with tamoxifen markedly inhibited the protein expressions of TLR4, NF-κB and the
downstream inflammatory agents, such as interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6),
and intercellular adhesion molecule-1 (ICAM-1). Administration of tamoxifen following SAH significantly ameliorated
the early brain injury (EBI), such as brain edema, blood-brain barrier (BBB) impairment, and clinical behavior scale.
Learning deficits induced by SAH were markedly alleviated after tamoxifen treatment.
Conclusions: Post-SAH tamoxifen administration may attenuate TLR4/NF-kappaB-mediated inflammatory response in
the rat brain and result in abatement of the development of EBI and cognitive dysfunction after SAH.
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Introduction
In China, stroke is the third leading cause of death,
approximately 20% of which are due to aneurysmal
subarachnoid hemorrhage (SAH) [1]. In the past three
decades, there are far more studies focusing on vasospasm
of the cerebral arteries than on the pathophysiological
changes in the brain after SAH, which also could lead to
disastrous outcomes [2]. Early brain injury (EBI) and sec-
ondary cognitive or neurobehavioral dysfunction after
SAH have been well documented, but the underlying
mechanisms still remain unclear [3]. On the one hand,
EBI is the most common cause of disability and mortality
in patients suffering from SAH. Treatment of EBI is
considered a major goal in the management of SAH
patients. However, the exact molecular mechanism of
EBI still remains unknown, which has hindered the
development of effective and specific treatment paradigms
for EBI [4]. On the other hand, approximately 50% of all
SAH patients die from EBI, and many of those who do
survive have lasting cognitive deficits [5]. Nowadays,
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treatment of cognitive dysfunction has also been considered
as a major target in the management of patients surviving
cerebral aneurysm rupture.
Tamoxifen is an antagonist of the estrogen receptor in
breast tissue via its active metabolite, hydroxytamoxifen.
In other tissues, it behaves as an agonist, and thus may be
characterized as a mixed agonist/antagonist [6]. Tamoxifen
is the usual endocrine (anti-estrogen) therapy for hormone
receptor-positive breast cancer in premenopausal women,
and is also a standard in postmenopausal women. Se-
veral previous reports from experimental studies have
demonstrated that tamoxifen plays neuroprotective roles in
spinal cord injury [7], intracerebral hemorrhage [8], brain
ischemia [9], and hypoxic-ischemic brain injury [10]. At
the same time, previous studies have proven that tamoxifen
could induce an anti-inflammatory response in acute
models of mouse and rat microglial cells; this response
seemed not to be estrogen receptor-mediated but probably
was attributable to some tamoxifen-induced modulation of
pro-inflammatory signaling cascades [11,12].
Nevertheless, until now it was unknown whether
tamoxifen could influence TLR4/NF-κB-related pro-
inflammatory pathways in the brain and decrease the
severity of brain injury after SAH. Thus, the aim of the
current study was to determine whether tamoxifen could
attenuate the SAH-induced activation of the TLR4/NF-κB
signaling pathway in the cortex and promote neurological
function and behavioral recovery after SAH.
Materials and methods
Animals
Male Sprague-Dawley (SD) rats (310 to 360 g; 12 weeks
old) were purchased from Animal Center of the Chinese
Academy of Sciences, Shanghai, China. The rats were
housed in temperature- and humidity-controlled animal
quarters with a 12-h light/dark cycle. All procedures were
approved by the Institutional Animal Care Committee of
Soochow University and were in accordance with the
guidelines of the National Institutes of Health on the care
and use of animals.
Following intraperitoneal anesthesia of an animal
with urethane (1,000 mg/kg), the animal’s head was
fixed in the stereotactic frame. The body temperature was
maintained at 37.5 ± 0.5°C with an automatic heating pad
(LSI Letica Scientific Instruments, Barcelona, Spain). The
tail artery was cannulated to measure mean arterial blood
pressure (MABP) and to obtain blood samples. The
animals were placed in a stereotaxic frame (David Kopf
Instruments, Tujunga, CA, USA) with the mouthpiece at
0°C. A laser Doppler flowmeter (LDF) (MBF3D, Moor
Instruments, Millwey, Axminster, Devon, UK) was used
for continuous monitoring of cerebral blood flow (CBF) in
the area of the cerebral cortex supplied by the middle
cerebral artery (MCA). To enable placement of the LDF
probes, a bur hole was drilled 5 mm left lateral and 1 mm
posterior to the bregma without injury to the dura mater.
Rat subarachnoid hemorrhage model
The experimental SAH model was produced using
stereotaxic insertion of a needle with a rounded tip and
a side hole into the prechiasmatic cistern according
to our previous study [13]. The amount of 0.3 ml
non-heparinized fresh autologous arterial blood was
slowly injected into the prechiasmatic cistern for 20 s
with a syringe pump under aseptic technique. Control
animals were injected with 0.3 ml saline. The animals
were allowed to recover 45 min after SAH. After operation
procedures, the rats were then returned to their cages and
the room temperature kept at 23 ± 1°C. Twenty milliliters
of 0.9% NaCl was injected subcutaneously right after the
operation to prevent dehydration. Heart rate and rectal
temperature were monitored, and the rectal temperature
was kept at 37 ± 0.5°C by using physical cooling (ice bag)
when required, throughout experiments. In the present
study, it was observed that the inferior basal temporal
lobe was always stained by blood. The tissue of the cortex
was separated on ice while being viewed under a micro-
scope and was frozen in liquid nitrogen immediately for
molecular biological and biochemical experiments.
Experimental design
As shown in Figure 1, we established four experimental
groups in a randomized fashion: (a) the control group
(n = 28), (b) the SAH group (n = 28), (c) the SAH + vehicle
group (n = 28), and (d) the SAH + tamoxifen group
(n = 28). Rats of the SAH + tamoxifen group received
5 mg/kg tamoxifen intraperitoneally (i.p.) at 2, 12, and 36 h
after the surgery. Rats of the SAH+ vehicle group received
equal volumes of 2-hydroxypropyl-β-cyclodextrin with the
same schedule. In the first experimental setting, the animals
were decapitated 48 h after injury for tissue assays. In the
second experiment, the animals were trained and evaluated
in a Morris water maze (MWM). The dose was chosen
according to Xie et al. [8] since they observed beneficial
effects on improving neurological function and reducing
brain edema in the intracerebral hemorrhage model.
Brain water content
Brain edema was determined using the wet/dry method as
previously described where percent brain water = ((wet
weight− dry weight) /wet weight) × 100% [14]. Briefly,
brains were rapidly removed from the skull and the bilateral
brains were separated. Both were placed separately into
pre-weighed and labeled glass vials and weighed. The vials
were then placed in an oven for 72 h at 100°C and then
re-weighed to obtain dry weight content. The number of
animals used in each group for brain edema study was
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control (n = 6), SAH (n = 6), SAH+ vehicle (n = 6) and
SAH+ tamoxifen (n = 6).
Blood-brain barrier permeability
Blood-brain barrier (BBB) permeability was determined
by Evans blue (EB) extravasation at 48 h after SAH.
Briefly, 2% Evans blue was injected intravenously at a
dose of 2 ml/kg. Animals were then re-anesthetized after
1 h with urethane (1,000 mg/kg) and perfused using
saline to remove intravascular EB dye. Animals were
then decapitated, and the entire brain of each was
removed and homogenized in phosphate buffered saline.
Trichloroacetic acid was then added to precipitate
protein, and the samples were cooled and centrifuged.
The resulting supernatant was measured for absorbance
of EB at 610 nm using a spectrophotometer. The number
of animals used in each group for the BBB permeability
study was control (n = 6), SAH (n = 6), SAH + vehicle
(n = 6) and SAH + tamoxifen (n = 6).
Neurologic scoring
Three behavioral activity examinations (Table 1) were
performed at 48 h after SAH using the scoring system
reported previously to record appetite, activity and
neurological deficits [15]. The number of animals used
in each group for neurologic scoring study was control
(n = 18), SAH (n = 18), SAH + vehicle (n = 18) and SAH+
tamoxifen (n = 18).
Western blot analysis
The frozen brain tissue was mechanically lysed in
20 mM Tris, pH 7.6, which contains 0.2% SDS, 1% Triton
X-100, 1% deoxycholate, 1 mM phenylmethylsulphonyl
fluoride (PMSF), and 0.11 IU/ml aprotinin (all purchased
from Sigma-Aldrich, Inc., St. Luis, MO, USA). Lysates
were centrifuged at 12,000 × g for 20 min at 4°C. The
protein concentration was estimated by the Bradford
method using the Nanjing Jiancheng (NJJC) protein
assay kit (Nanjing Jiancheng Bioengineering Institute,
Nanjing, China). The samples (60 μg per lane) were
separated by 8% SDS-PAGE and electro-transferred
onto a polyvinylidene-difluoride (PVDF) membrane
(Bio-Rad Laboratories, Hercules, CA, USA). The membrane
was blocked with 5% skimmed milk for 2 h at room
temperature, incubated overnight at 4°C with primary
antibodies directed against the TLR4, NF-κB P50, and
ICAM-1 (all from Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) in PBS + Tween 20 (PBST) at
dilutions of 1:200, and β-tubulin (diluted 1:8000 in
PBST, Sigma-Aldrich, Inc., St. Luis, MO, USA) was
used as a loading control. We detected TLR4 at 95 kDa,
NF-κB at 50 kDa, ICAM-1 at 60 kDa, and β-tubulin at 50
kDa. After the membrane was washed for 10 min each for
six times in PBST, it was incubated in the appropriate
HRP-conjugated secondary antibody (diluted 1:400 in
PBST) for 2 h. The blotted protein bands were visualized
by enhanced chemiluminescence (ECL) Western blot
detection reagents (Amersham, Arlington Heights, IL, USA)
Figure 1 Experimental design.
Table 1 Behavior and activity scores
Category Behavior Score
Appetite Finished meal 0
Left meal unfinished 1
Scarcely ate 2
Activity Walk and reach at least three corners of the cage 0
Walk with some stimulation 1
Almost always lying down 2
Deficits No deficits 0
Unstable walk 1
Impossible to walk 2
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and were exposed to X-ray film. Developed films were
digitized using an Epson Perfection 2480 scanner
(Seiko Corp, Nagano, Japan). Optical densities were
obtained using Glyko Bandscan software (Glyko, Novato,
CA, USA) and the protein expression levels were normal-
ized to β-tubulin.
Nuclear protein extract and electrophoretic mobility
shift assay
Nuclear protein was extracted and quantified as described
[16]. Electrophoretic mobility shift assay (EMSA) was
performed using a commercial kit (Gel Shift Assay System;
Promega, Madison, WI, USA) following the methods
in our laboratory. The NF-κB oligonucleotide probe
(5’-AGTTGAGGGGACTTTCCCAGGC-3’) was end-labeled
with [γ-32P]ATP (Free Biotech, Beijing, China). EMSA
was performed according to our previous study [16].
Enzyme-linked immunosorbent assay
The levels of inflammatory mediators were quantified
using specific ELISA kits for rats according to the manu-
facturers' instructions (TNF-α from Diaclone Research,
Besançon, France; IL-1β, IL-6 from Biosource Europe SA,
Nivelles, Belgium) and our previous study [16]. Values
were expressed as ng/g protein.
Behavior testing
Spatial learning and memory were assessed using a
modified version of the Morris water maze (MWM)
including cued learning procedure, spatial acquisition
task, reference memory task, and working memory task
according to the previous study [17]. A camera mounted
in the center of the ceiling above the pool tracked the
rat (Poly Track System, San Diego Instruments, San
Diego, CA, USA). Behavior testing was performed
between 10:00 and 18:00. All animals were housed at
a constant temperature of 22°C, under a 12-h light/dark
cycle (light switched on at 6:00 AM), with free access to
food and water. The number of animals used in each group
for MWM study was control (n = 10), SAH (n = 10),
SAH + vehicle (n = 10) and SAH + tamoxifen (n = 10).
Experiments for tamoxifen study in control rats
For evaluating the effects of tamoxifen in control rats,
we established two experimental groups in a randomized
fashion: the control + vehicle group (n = 8) and the con-
trol + tamoxifen group (n = 8). Rats of control + tamoxifen
group received 5 mg/kg tamoxifen i.p. at 2, 12, and 36 h
after the sham surgery. Rats of control + vehicle group re-
ceived equal volumes of 2-hydroxypropyl-β-cyclodextrin
with the same schedule. The animals were decapitated
48 h after sham injury for tissue assays.
Statistical analysis
All data were presented as mean ± SD. SPSS 12.0 was
used for statistical analysis of the data. All data were
subjected to a one-way ANOVA. Differences between
experimental groups were determined by Fisher’s LSD
post-test. Statistical significance was inferred at P <0.05.
Results
General observation
No significant changes in body weight, MABP, temperature,
or injected arterial blood gas data were detected in any of
the experimental groups (data not shown). The mortality
rate of rats in the control group was 0% (0/28 rats), and it
was 20% (21/105 rats) in the SAH group. As shown in
Figure 2A, the rats in SAH groups exhibited blood clots
over the basal surface of the brainstem and Willis circle.
The data of CBP and MABP are shown in Figure 2B
and 2C. In SAH group, CBF decreased from 23.1 ± 1.6 to
3.7 ± 1.1 TFU within 20 s during the blood injection, and
then increased to the baseline in 25 min (Figure 2B). After
SAH, MABP increased immediately from 83.4 ± 5.3 to
134.5 ± 4.1 mmHg, but returned to values of baseline
within 15 min (Figure 2C).
Tamoxifen ameliorated early brain injury after experimental
subarachnoid hemorrhage
A significant increase (P <0.05) in water content was
detected in the brain samples of injured side at 48 h
after SAH when compared with rats in control group
(Figure 3A). The mean value of brain water content in
the brain was decreased by tamoxifen administration
(P <0.05) as compared with SAH + vehicle group. The
pattern of Evans blue extravasation following SAH is
shown in Figure 3B. Rats in SAH and SAH + vehicle
groups demonstrated a significant increase (P <0.01)
in BBB permeability to Evans blue relative to rats of
control group. Administration of tamoxifen significantly
inhibited Evans blue extravasation (P <0.01), indicating a
reduced BBB opening in response to tamoxifen treatment.
As compared with the control group, clinical behavior
function impairment caused by SAH was evident in SAH
subjects (P <0.01, Figure 3C). No significant difference
was seen between the SAH group and SAH+ vehicle
group (P >0.05). Tamoxifen treated rats showed better
performance in this scale system than vehicle-treated rats
at 48 h after SAH (Figure 3C), and the difference was
statistically significant (P <0.01).
Western blot analysis for detecting TLR4, NF-κB, and
ICAM-1 expressions after subarachnoid hemorrhage
The protein levels of TLR4, NF-κB, and ICAM-1 were
detected by western blot. These proteins were expressed
at a low level in the rat brains of control group. The
levels of TLR4, NF-κB, and ICAM-1 were significantly
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Figure 3 Alterations in brain water content in control group (n = 6), subarachnoid hemorrhage (SAH) group (n = 6), SAH + vehicle
group (n = 6), and SAH + tamoxifen group (n = 6). (A) The brain water content was increased significantly at 48 h after SAH. Tamoxifen
treatment markedly reduced brain water content. (B) Alterations in Evans blue extravasation in control group (n = 6), SAH group (n = 6), SAH + vehicle
group (n = 6), and SAH + tamoxifen group (n = 6). SAH could induce a marked increase of blood-brain barrier (BBB) extravasation in the rat brain
compared with control group. After tamoxifen administration, the Evans blue extravasation was significantly reduced as compared with SAH + vehicle
group. (C) Effects of tamoxifen administration on functional outcomes in the control group (n = 18), SAH group (n = 18), SAH + vehicle group (n = 18),
and SAH + tamoxifen group (n = 18). Compared to rats in SAH + vehicle group, Tamoxifen administration attenuated the SAH-induced impairment in
the performance tested at 48 h after SAH. *P <0.05 and **P <0.01 between control animals versus SAH animals; #P <0.05 and ##P <0.01
between SAH + vehicle animals versus SAH + tamoxifen animals; n.s. P >0.05 between SAH animals versus SAH + vehicle animals.
(See figure on previous page.)
Figure 2 Schematic representation of the analyzed area induced by subarachnoid hemorrhage (SAH). (A) control group and (B) SAH
group. C and D: The time course of cerebral blood flow (CBF) and mean arterial blood pressure (MABP) in control group (n = 18), SAH group
(n = 18), SAH + vehicle group (n = 18), and SAH + tamoxifen group (n = 18). (C) Graphs of CBF in middle cerebral artery (MCA) area measured by
continuous laser Doppler flowmeter over the left hemisphere. (D) Secondary to injection of saline or blood, MABP increased sharply in all four
groups. *P <0.05 and **P <0.01 between control animals versus SAH animals.
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increased in the cortex in SAH group as compared
with that of control group (P <0.05). The protein
expressions had no significant difference between SAH
group and SAH+ vehicle group (P >0.05). The expressions
of TLR4, NF-κB, and ICAM-1 in the brains of SAH+
Tamoxifen group were significantly lower than those of
the SAH + vehicle group (P <0.05, Figure 4).
Tamoxifen administration inhibited NF-κB DNA binding
activity after subarachnoid hemorrhage
EMSA autoradiography of NF-κB DNA binding activity
of the brain samples was shown in Figure 5. Low NF-κB
binding activity (weak EMSA autoradiography) was
found in the control group. Compared with control
group, NF-κB binding activity in the injured brain
was significantly increased (P <0.01) in SAH and
vehicle-treated groups. In SAH + tamoxifen group, the
NF-κB binding activity was significantly downregulated
(P <0.05) in the brain area surrounding the blood clot
site after SAH.
Tamoxifen treatment decreased cortical levels of
pro-inflammatory cytokines following subarachnoid
hemorrhage
Concentrations of IL-1β, TNF-α and IL-6 were low in
the rat brains of control group (Figure 6). Compared
with control group, cortical levels of the three inflammatory
cytokines were greatly induced after SAH. As shown
in Figure 6, tamoxifen administration after SAH could
lead to significantly decreased IL-1β, TNF-α and IL-6
concentrations.
Behavior testing
The facility of MWM was shown in Figure 7, and one of
the representative trials in each group was also indicated
in Figure 7. For all behavioral measurements, swimming
Figure 4 Representative autoradiogram of TLR4, NF-κB, and ICAM-1 expression in the brain after subarachnoid hemorrhage (SAH).
Upper: We detected TLR4 at 95 kDa, NF-κB at 50 kDa, ICAM-1 at 60 kDa, and the loading control β-tubulin at 50 kDa. It shows that the expression
of these proteins was increased in the SAH groups and downregulated after tamoxifen treatment. Lane 1, control; lane 2, SAH; lane 3, SAH + vehicle;
lanes 4, SAH + tamoxifen, respectively. Bottom: Quantitative analysis of the Western blot results shows that these protein levels in SAH groups are
significantly higher than in the control group and were inhibited by tamoxifen. Bars represent the mean ± SD (n = 6, each group). **P <0.01 between
control animals versus SAH animals; #P <0.05 and ##P <0.01 between SAH + vehicle animals versus SAH + tamoxifen animals; n.s. P >0.05 between SAH
animals versus SAH + vehicle animals.
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speed and thigmotaxis (percent time spent in the perimeter
of the pool) were evaluated and found not significantly
different among the four groups except for four rats with
hemiparesis that spent significantly more time in the
perimeter and showed swim-overs and jump-offs. These
four animals were excluded from the present study.
Rats usually can find the visible platform. They usually
found the platform on the first trial, even if they failed
the trial, which happened equally across the groups.
There was no difference in the escape latency and
swimming speed in the cued learning procedure between
the four groups (P >0.05). Spatial learning was also the
same for all four groups during the second and third days
after blood injection. Spatial learning deficits appeared
during the fourth and fifth days in the SAH group as
compared to controls. The tamoxifen group exhibited
significantly shorter escape latency than the vehicle
group during the fourth and fifth days (Figure 7A,B).
Animals of all four groups learned to find the platform to
escape from water within each testing day (Figure 7A-D).
But the SAH group was significantly impaired compared
to controls (the fourth and fifth days), which was alleviated
by tamoxifen compared to the vehicle group. Repeated
measures ANOVA indicated a significant difference in
escape latency (Figure 7A, P <0.01) and in swimming
distance (Figure 7C, P <0.01) between the SAH group and
control groups, which was also improved by tamoxifen
compared to the vehicle group. When the escape latency
and swimming distance from all of the testing days was
separated into the four daily trials, the escape latency of
the SAH group was significantly longer compared to the
control group. The tamoxifen group’s escape latency was
significantly shorter than the vehicle group (Figure 7B,
P <0.01). But in swimming distance, only the tamoxifen
group performed significantly compared to the vehicle
group on the 4th day (Figure 7D, P <0.01).
The percent improvement in latency of the SAH group
decreased significantly by day five (Figure 7E, P <0.01), while
rats in the control groups had gradual, non-significant
decreases in percent improvements. However, the percent
improvement of the tamoxifen group appeared as negative
growth by day four. There was no significant difference
between the groups in reference memory as measured by
the percent time spent in the target quadrant in the probe
Figure 5 NF-κB activity in the brain area surrounding the blood clot in control group (n = 6), subarachnoid hemorrhage (SAH) group
(n = 6), SAH + vehicle group (n = 6), and SAH + tamoxifen group (n = 6). Upper, electrophoretic mobility shift assay (EMSA) autoradiography
of NF-κB DNA binding activity. Lane 1, control; lane 2, SAH; lane 3, SAH + vehicle; lane 4, SAH + tamoxifen, respectively. Bottom, Levels of NF-κB
DNA binding activity quantified by computer-assisted densitometric scanning and expressed as arbitrary densitometric units (ADU). **P <0.01
between control animals versus SAH animals; #P <0.05 between SAH + vehicle animals versus SAH + tamoxifen animals; n.s. P >0.05 between SAH
animals versus SAH + vehicle animals.
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trial, although there was a trend towards fewer annulus
crossings between the four groups (data not shown).
Animals in the control group showed significantly
longer times except for the sixth day on the working
memory task when compared to the SAH groups, as
shown by the time saved in latency for finding the
platform on the second trial compared to the first
trial. However, there was no significant difference
among the tamoxifen group and the vehicle group
(Figure 7F, P >0.05).
Effects of tamoxifen administration on control rats
As shown in Figure 8, the protein levels of TLR4,
NF-κB, and ICAM-1 were expressed at a low level in the
rat brains of control + vehicle and control + tamoxifen
groups and the difference was not significant (P >0.05).
Compared with control + vehicle group, NF-κB binding
activity in the brain was not significantly changed in
control + tamoxifen group (P >0.05). The mean value of
brain water content in the brain did not change significantly
by tamoxifen administration in control rats (P >0.05).
Discussion
The main findings of this study are as followings: 1) after
tamoxifen administration, early brain damages such as
brain edema, BBB permeability, and clinical scales were
ameliorated after SAH; 2) the upregulated cortical levels
of these agents related to the TLR4/NF-κB inflammatory
signaling pathway were attenuated when treated with
tamoxifen at the level of protein synthesis; 3) after intra-
peritoneal administration of tamoxifen, SAH-induced
behavior and cognitive dysfunction were attenuated in
this prechiasmatic blood injection model. These findings
suggest for the first time that tamoxifen may attenuate the
SAH-induced TLR4/NF-κB signaling pathway activation,
which may facilitate the development of secondary brain
damage following SAH. This neurobehavioral study leads
to the hypothesis that decrease of inflammatory path-
way in the brain may be important in modulating the
function of cognition, and we tentatively suggest that
this phenomenon may be involved in the mechanism
of neurobehavioral dysfunction after SAH.
There have been several studies focusing on the neu-
roprotective effects of tamoxifen in other nerve injury
models. Tian et al. [7] investigated whether tamoxifen
could inhibit inflammatory response, reduce cell apoptosis,
decrease myelin loss and ameliorate impaired behavior
after adult rat spinal cord injury (SCI). Their results
suggested that tamoxifen treatment attenuated post-
traumatic inflammatory damage, alleviated neuronal apop-
tosis, decreased myelin loss and production in axonal
outgrowth inhibitors, and resulted in improved functional
outcome after SCI. In more recent data, Xie et al. [8]
demonstrated in an intracerebral hemorrhage model that
tamoxifen at 5 mg/kg reduced perihematomal brain
edema, decreased caudate atrophy, and improved functional
outcome. In this current research, our data are consistent
with the previous studies. We found that tamoxifen admin-
istration following SAH could reduce cerebral edema,
BBB permeability and neurologic scoring, which played
important roles in EBI following SAH. At the same time,
neurobehavioral results that are consistent with our
speculation show that rats treated with tamoxifen exhibit
a better performance in comparison to vehicle-treated
rats in MWM testing, suggesting that downregulation
of TLR4/NF-κB signaling may improve the SAH-induced
spatial working memory dysfunction.
In the previous research regarding tamoxifen and
inflammation, Chuang et al. [18] investigated the baseline
levels of NF-κB activity of representative carcinoma cell
lines, and the change of NF-κB activity in response to a
challenge with tamoxifen treatment. They suggest that
tamoxifen treatment significantly attenuated doxorubicin-
induced NF-κB activation in the cells. Another research
investigated whether tamoxifen alleviated inflammatory
damage seen in the irradiated microglia in vitro and
in the irradiated brain [19]. Tamoxifen administration
(i.p., 5 mg/kg) immediately post-radiation reduced the
irradiation-induced brain damage after whole brain irradi-
ation (WBI), which included injuries of BBB permeability
Figure 6 Changes of inflammatory mediators in the injured
brains as determined by ELISA in control group (n = 6),
subarachnoid hemorrhage (SAH) group (n = 6), SAH + vehicle
group (n = 6), and SAH + tamoxifen group (n = 6). SAH could
induce the significantly increased concentrations of IL-1β, TNF-α and
IL-6 in the rat brain after SAH. In SAH + tamoxifen group, the cortical
concentrations of IL-1β, TNF-α, and IL-6 were markedly downregulated
following SAH. *P <0.05 and **P <0.01 between control animals versus
SAH animals; #P <0.05 and ##P <0.01 between SAH + vehicle animals
versus SAH + tamoxifen animals; n.s. P >0.05 between SAH animals
versus SAH + vehicle animals.
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and tissue edema formation. Furthermore, tamoxifen
downregulated WBI-induced microglial activation and
reactive astrogliosis by attenuating the pro-inflammatory
cytokine expression of IL-1β and TNF-α [19]. In the
present study, we found that the levels of TLR4/ NF-κB
pathway in the brain were activated following SAH and
could be suppressed after tamoxifen administration, which
is in agreement with the previous studies from other in vivo
and in vitro models. However, the potential mechanism
underlying the initial effect on TLR4/NF-κB signaling
pathway following SAH remains unclear. The main TLR4
ligands in the brain after SAH and the whole mechanism
related to tamoxifen call for further research.
Studies from basic research and clinical trial have
demonstrated that inflammation played important roles
in the pathophysiological process of SAH [20]. TLR4/
NF-κB signaling pathway has also been proven to be ac-
tivated in both injured brain tissue and spasmodic ce-
rebral artery of SAH models in our previous studies
[21,22]. Our present data proved that tamoxifen might
repress the expressions of TLR4/NF-κB related inflamma-
tory agents, which could lead to downregulation of cerebral
inflammation after SAH. We tentatively suggest that due to
the anti-inflammatory effect of tamoxifen administration,
the learning and memory ability tested by cued learning
procedure, spatial acquisition task, reference memory task,
and working memory task were turned better following
experimental SAH. Future research will be designed to look
inside the mechanism of the whole signaling pathway of
inflammatory response, to look for the key cell type in the
brain after SAH, and to find out the exact organelles that
were responsible for the transduction of the TLR4/NF-κB
pathway. Previous studies concerning estrogen receptor
modulators and inflammation indicated that glial cells
(microglia and astroglia) might play an important role
in this molecular mechanism [23,24]. Tamoxifen may
be a candidate to counteract brain inflammation under
neurodegenerative conditions by targeting the production
and release of pro-inflammatory molecules by glial cells.
Conclusions
To the best of our knowledge, this study is the first one to
evaluate the effect of tamoxifen on the EBI and on second-
ary neurobehavioral dysfunction in this experimental SAH
model, as well as the influence of tamoxifen on TLR4/NF-
κB pro-inflammatory pathway after SAH. We found that
SAH could upregulate the protein expressions of TLR4/
NF-κB pathway-related mediators, upstream factors
(TLR4 and NF-κB) and downstream factors (IL-1β, TNF-α,
IL-6, and ICAM-1), in the brain surrounding the blood
clot, which could be markedly inhibited by tamoxifen ther-
apy. These results suggest that SAH could induce an acti-
vation of the TLR4/NF-κB signaling pathway in the rat
brain, which might play a central role in the inflammatory
response that leads to secondary insults after SAH. The
therapeutic benefit of post-SAH tamoxifen administration
might be due to its salutary effect on modulating the
TLR4/NF-κB signaling pathway.
(See figure on previous page.)
Figure 7 Representative images of the Morris water maze (MWM) trials of the rats of four groups. Bottom: Spatial learning and memory
in the MWM. Escape latency and swimming distance over 16 trials (A, C) and averaged for each day (B, D) over days 2 to 5. The percent
improvement in escape latency from the previous training day was significantly lower on day five in the subarachnoid hemorrhage (SAH) group
as compared to controls (E, *P <0.01). The tamoxifen group was higher on day four than the vehicle group (E, #P <0.01). The control group
exhibited significantly longer time except on day 6 as compared to the SAH group on the working memory task (matching-to-place task) by the
time saved in latency for finding the platform on the second (test) trial compared to the first (sample) trial (F, *P <0.01). There was no significant
difference between the tamoxifen group and the vehicle group (values are means ± SD, n = 10 per group).
Figure 8 No significant influence of tamoxifen on control rats. (A) Western blot; (B) electrophoretic mobility shift assay (EMSA), lane 1,
control + vehicle, lane 2, control + tamoxifen; (C) Water content analysis.
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